RedHill Biopharma (RDHL) Operating Leases (2019 - 2025)

RedHill Biopharma (RDHL) has 7 years of Operating Leases data on file, last reported at $900000.0 in Q4 2025.

• On a quarterly basis, Operating Leases rose 154.96% year-over-year to $900000.0 in Q4 2025; TTM through Dec 2025 was $900000.0, a 154.96% increase from a year earlier, with the FY2025 full-year figure at $900000.0, up 154.96% from the prior year.
• Operating Leases for Q4 2025 stood at $900000.0, up from $214000.0 in the prior quarter.
• Over the last five years, Operating Leases for RDHL reached as high as $7.2 million in Q1 2022 and fell as low as $214000.0 in Q2 2025.
• Historically, Operating Leases has averaged $3.2 million across 5 years, with a median of $2.8 million in 2021.
• Across the five-year window, Operating Leases plunged 88.86% in 2023 and soared 154.96% in 2025, its largest moves.
• Year by year, Operating Leases stood at $2.6 million in 2021, then jumped by 150.31% to $6.4 million in 2022, then plunged by 88.86% to $718000.0 in 2023, then plunged by 50.84% to $353000.0 in 2024, then surged by 154.96% to $900000.0 in 2025.
• Per Business Quant data, the three most recent Operating Leases figures were $900000.0 in Q4 2025, $214000.0 in Q2 2025, and $353000.0 in Q4 2024.